This month, we are highlighting promising work by Professor Hirofumi Hanaoka’s team at Kansai Medical University, Photo-ImmunoTherapy Research Institute. They developed a novel peptide-based photoimmunotherapy drug that targets PD-L1, which is expressed on many types of cancer cells. Preclinical experiments showed significant suppression of tumor growth and an extended overall survival rate, when drug was activated with near-infrared laser using the ML7710 laser system. From a translational perspective, this peptide-based drug offers advantages over antibody-based drugs, such reduced production costs, rapid tumor accumulation, better tumor penetration, and accelerated systemic clearance that may mitigate photosensitivity risks.

Modulight is very happy to be supporting this research. We would like to deliver our warmest congratulations to the research team!

#Laser-Sharp Research  #photoimmunotherapy  #nextgenerationtherapies  #lasertherapy #peptides #antibodies

Modulight products used:

Read more:

About Modulight’s LASER-SHARP RESEARCH concept:

Laser-Sharp Research is a concept where our scientific board highlights cutting-edge scientific research articles from our customers. Important selection criteria are that Modulight and laser product are mentioned in the publication, the impact and relevance of the results, clinical translatability, as well as scientific quality of the journal. The nominated research groups will be rewarded to encourage the great work done.